Neoadjuvant chemotherapy (NAC) for breast cancer is increasingly used in clinical practice. Standard imaging assess-ment provides important information for treatment response and is the guarantee of neoadjuvant therapy. This article discussed the advantages and limitations of assessment modalities including mammography (MG)

ultrasound

magnetic resonance imaging (MRI) and PET/CT

as well as their value in the treatment process

and the research progress of emerging techniques.